Description: A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Mechanism of Action: Monoclonal antibody that specifically binds the NKG2D ligands MICA and MICB and prevents their proteolytic release from the surface of tumor cells, thereby enhancing tumor cell lysis by NKG2D-expressing immune cells.
Target Patient Population: All solid tumors. Monotherapy arms and combination arms administered with Pembrolizumab
Study Design: Drug is administered IV weekly in a 21 day cycle